“…CD274 [175], CEACAM1 [176], STAT1 [177], ARG1 [178], TLR4 [179], LRRK2 [180], ABCA1 [181], IFIH1 [182], TLR5 [183], PTGS2 [184], CYP2D6 [185], RNF213 [186], C9ORF72 [187], JAK2 [188], TLR8 [189], NOTCH2 [190], PDGFC (platelet derived growth factor C) [191], TLR2 [192], PRKAB2 [193], HDAC9 [194], NCOA4 [195], LATS2 [196], DICER1 [197], IL1RN [198], GCH1 [148], EGR1 [199], HIPK3 [200], ZEB2 [201], HIF1A [202], PLA2G7 [203], DOCK8 [204], CCR2 [205], PPP1R15B [206], GCLC (glutamate-cysteine ligase catalytic subunit) [207], VEGFA (vascular endothelial growth factor A) [208], SORL1 [209], OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) [210], EIF2AK3 [211], SLC40A1 [212], PHLPP1 [213], IGF2R [214], LPIN2 [215], SIRT1 [216], VPS13C [217], ACSL4 [218], ELOVL6 [219], FGL2 [220], ERO1B [221], XAF1 [222], TET2 [223], TET3 [224], PF4 [225], POU2F1 [226], PC (pyruvate carboxylase) [227], NDUFS8 [228], PRDX2 [229], RUNX3 [230], HSPB1 [231], TCF4 [169], TCF7 [232], IGFBP4 [233], HSPG2 [234], NMRAL1 [173], AQP3 [235] and LGALS3 [236] might be a potential therapeutic target for diabetes mellitus. Studies have found that CEACAM1 [237], STAT1 [238], ARG1 [239], TLR4 [240], LRRK2 [241], ABCA1 [242], PTGS2 [243], CYP2D6 [244], JAK2 [245], TLR2 […”